TLT laser receives FDA clearance

Article

SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced.

SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced. The laser had already been licensed for use in the EU and Canada.

A randomized international multicentre trial enrolled more than 180 subjects to compare TLT with argon laser trabeculectomy (ALT) for intraocular pressure (IOP) reduction. Study subjects had primary open angle glaucoma and poorly controlled IOP on maximally tolerated medications and/or prior failed trabeculoplasty.

At the 12 month follow-up visit, subjects in the TLT treatment arm had achieved a mean IOP reduction of 25.8% (6.8±4.7 mmHg), which had been achieved immediately and maintained throughout the study period; ALT-treated subjects experienced an IOP reduction of 22.2% (5.7±4.8 mmHg). The laser was also found not to cause thermal damage to the trabecular meshwork.

As the TLT treatment was found to be equivalent to ALT treatment, FDA approval for the SOLX 790 laser was granted.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.